Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
Publication/Presentation Date
5-4-2018
Abstract
Chimeric antigen receptor (CAR) T cell therapy is genetically engineered tumor antigen-specific anticancer immunotherapy, which after showing great success in hematological malignancies is currently being tried in advanced solid tumors like pancreatic cancer. Immunosuppressive tumor microenvironment and dense fibrous stroma are some of the limitation in the success of this novel therapy. However, genetic modifications and combination therapy is the topic of the research to improve its efficacy. In this article, we summarize the current state of knowledge, limitations, and future prospects for CAR T cell therapy in pancreatic cancer.
Volume
35
Issue
6
First Page
84
Last Page
84
ISSN
1559-131X
Published In/Presented At
Jindal, V., Arora, E., Masab, M., & Gupta, S. (2018). Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice. Medical oncology (Northwood, London, England), 35(6), 84. https://doi.org/10.1007/s12032-018-1145-0
Disciplines
Medicine and Health Sciences
PubMedID
29728788
Department(s)
Department of Obstetrics and Gynecology
Document Type
Article